Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Phase 1b/2 Clinical Study of an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy (C-CAR168) for the Treatment of Progressive Multiple Sclerosis Refractory to Standard Therapy

NCT07825389 is registered in ClinicalTrials.gov with AbelZeta Inc. as lead sponsor.

NCT NCT07825389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07825389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Phase 1b/2 Clinical Study of an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy (C-CAR168) for the Treatment of Progressive Multiple Sclerosis Refractory to Standard Therapy
Lead sponsor
AbelZeta Inc.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
February 28, 2027
Completion date
February 28, 2030
Enrollment
119 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune, ms, ms (multiple sclerosis), multiple sclerosis, neuro-degenerative disease, neuro-degenerative diseases, primary progressive multiple sclerosis, primary progressive multiple sclerosis (ppms), secondary progress multiple sclerosis (spms)